BioHealth Innovation, Inc. (BHI) is seeking a half-time Entrepreneur-in-Residence (EIR) to join their team at the National Institutes of Health (NIH). The EIR will provide product, corporate, and private investment strategies for NIH-funded R&D teams and small businesses ready to take the next step toward commercial success.

As the world’s largest early-stage biomedical investor, the NIH is committed to accelerating the conversion of scientific discoveries into healthcare solutions. Working directly with NIH staff and the portfolios of early-stage R&D teams and small businesses to mentor and enable business/product development, they will bring, build, and expand networks with private and corporate investors and related stakeholder organizations with a strategic interest in early-stage biomedical technologies.

The EIR will also support existing initiatives for early-stage product development and ideate, plan, and help to implement new programs. They will engage and partner with investment associations, economic development, and business organizations for additional support to enhance NIH innovators’ commercial success across the US. This role will also present and coordinate investor forums, conferences, and other networking opportunities for early-stage life science companies, scientists, universities, associations, and federal laboratories.

Click here to view and role description.

Catalyze Preclinical Services Program

The Preclinical Services Program expands the support available to innovators with a heart, lung, blood, or sleep to include preclinical development activities from end-stage proof-of-concept through preclinical development and US regulatory submissions. Preclinical services are tailored to the development needs of each product. Applicants can request specific services required to advance their technology to the clinic or regulatory submission. Once a project is selected for support, the level of support and services provided are negotiated between the Principal Investigator and NHLBI.

GAITHERSBURG, MD / ACCESSWIRE / February 23, 2023 / BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced a co-development arrangement with the J. Craig Venter Institute (JCVI), a world-leading institution in genomics research and innovation, for the design and validation of a synthetic HSV-1 (herpes simplex type 1) virus particle targeting colorectal cancer.

Exciting News: #AGT CEO, Jeff Galvin, won “the most prestigious leadership award in the life sciences industry” — The Life Sciences Voice Top Industry Leaders Award! It recognizes the industry's most creative minds working on important initiatives and delivering extraordinary results. Read more. https://bit.ly/3IMfVyC

I write today to announce that Dr. Tatiana Litvin-Vechnyak, currently Associate Vice President for Innovation Ventures at Rutgers University, will serve as Georgetown University’s new Vice President for Technology Commercialization starting February 1, 2023.

Dr. Litvin-Vechnyak brings significant experience and expertise to this critical role, having led the Rutgers Innovation Ventures team’s management of approximately 1,260 technologies, 2,600 patent assets, 800 licenses and 90 startup companies. She holds a Ph.D. in Pharmacology from Cornell University Weill Graduate School of Medical Sciences and a B.A. in Biochemistry and Molecular Biology from Clark University. She has done Postdoctoral Research at Rutgers Cancer Institute of New Jersey where she was a recipient of the Gallo Award for Outstanding Cancer Research. Dr. Litvin-Vechnyak is a Registered Patent Agent; has served on a number of boards over the years, including the Research & Development Council of New Jersey; and was recently elected to the Board of Directors of AUTM -the Association of University Technology Managers.

CHARLOTTESVILLE, Va., February 28, 2023 -- AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is irreversible and providing decision support for prophylactic therapies.  Genes that drive the inflammatory pathways characteristic of different stages of kidney damage are revealed in the peer-reviewed journal Frontiers in Immunology.  AMPEL's breakthrough approach identified markers in kidney biopsy samples that drive pathways that can be targeted by drugs.  The NephroGENE^® lab test, only a concept for the last few years, is now ready for development for practical use as a decision support biomarker test to manage kidney disease.

AMPEL's innovation is crucial to provide decision support for day-to-day patient care as well as effective drug development.  Currently, physicians rely on microscopic examination of kidney biopsies to assess the severity of disease and there is no current way to predict drug options.  Today's publication identifies the molecular pathways at every stage of damage leading to end stage renal disease as well as targets of medications to slow down the immune driven damage.  And translation of key genes in animal models used for Lupus Nephritis drug development with human patients is essential to increase the success rate of clinical trials and provide earlier confirmation of the applicability of pre-clinical work to human disease.

Jacob Greenwood, Director of Business Development at CRB, joins BioTalk with Rich Bendis to discuss engineering in the industry, the Chesapeake Bay Area Chapter of ISPE, and his career in the BioHealth Capital Region.

Listen now via Apple https://apple.co/3lO9SQZ, Google https://bit.ly/41g3diC, Spotify https://spoti.fi/3xG8OkN, Amazon https://amzn.to/3SfEKpQ, and TuneIn https://bit.ly/3xG9M0I